Cloudbreak®
Cidara is developing a new generation of immunotherapeutic agents from its Cloudbreak platform that couple potent drugs to a human antibody fragment. These highly potent, long-acting drug-Fc conjugates (DFCs) are designed to inhibit specific disease targets while simultaneously engaging the immune system.
DFCs have the potential to treat and prevent SARS-CoV-2 and other life-threatening viruses. Preclinical and discovery efforts are ongoing.
Subscribe here for updates.
